Lynda Grine, EADV Spring Symposium 2021: Intermittent Fasting in Psoriasis
It was a pleasure to speak with Dr Lynda Grine (Ghent University Hospital, Ghent, Belgium) about her research into the effects of intermittent fasting on psoriasis.
Her presentation entitled ‘Interim results of the MANGO trial: effects of modified intermittent fasting in psoriasis’ was presented at the EADV Spring Symposium, 6-7 May 2021.
- Could you give us a brief overview of the comorbidities, including metabolic syndrome and leaky gut syndrome, associated with psoriasis? (0:05)
- What is the rationale for intermittent fasting in psoriasis patients? (1:19)
- Could you tell us a little about the MANGO trial protocol? (3:21)
- When will the results be available? (4:47)
Disclosures: Dr Lynda Grine has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed as a highlight of EADV Spring 2021 (Virtual).
Share this Video
Related Videos In Psoriasis
Alan Menter, Dermatology Meeting News 2023: Ixekizumab treatment for patients with moderate-to-severe plaque psoriasis
Ixekizumab is a humanized monoclonal antibody currently approved in patients with moderate-to-severe plaque psoriasis. We caught up with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA) to discuss the aims, design, inclusion criteria and main findings of a post-hoc analysis conducted on trials studying the use of ixekizumab in adult and paediatric patients […]
Alan Menter, Dermatology Meeting News 2023: Clinical presentations and unmet needs of palmoplantar psoriasis
Palmoplantar psoriasis has a significant impact on patients’ quality of life and can be challenging to treat. touchIMMUNOLOGY were delighted to speak with Dr Alan Menter (Baylor University Medical Center, Dallas, TX, USA), about the prevalence and clinical presentations of palmoplantar psoriasis, its impact on quality of life, and the unmet needs in its treatment. […]
Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis
Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor approved for the treatment of moderate to severe plaque psoriasis, a post-hoc analysis of the phase 3 POETYK PSO-1 and PSO-2 trials investigated the efficacy of deucravacitinib by baseline characteristics in this indication. touchIMMUNOLOGY were delighted to speak with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!